CareDx, Inc. specializes in creating diagnostic solutions tailored for transplant patients, offering a suite of products that monitor the health and acceptance of organ transplants. Their innovative offerings include AlloSure for kidney, heart, and lung transplant patients, which uses donor-derived cell-free DNA to detect organ rejection. Additionally, CareDx provides AlloMap Heart, a gene expression test for heart transplant recipients, and a range of HLA typing solutions like Olerup SSP and QTYPE. They also offer Ottr, a software for managing transplant patients, and AlloCare, a mobile app designed to support transplant recipients' journeys. Headquartered in South San Francisco, California, CareDx serves its products globally, directly and through distributors.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Apple, Array Technologies, CareDx and Vertex Pharmaceuticals.
